A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia

References

• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How i treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436.
   PubMed Web of Science ®Google Scholar
• Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656.
   PubMed Web of Science ®Google Scholar
• Socié G. Allogeneic bm transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematol Am Soc Hematol Educ Program. 2013;2013:82–86.
   PubMedGoogle Scholar
• Bacigalupo A, Socié G, Hamladji RM, et al. Current outcome of hla identical sibling versus unrelated donor transplants in severe aplastic anemia: An ebmt analysis. Haematol. 2015;100(5):696–702.
   PubMed Web of Science ®Google Scholar
• Xu LP, Wang SQ, Wu DP, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265–274.
   PubMed Web of Science ®Google Scholar
• Liu HL, Sun ZM, Geng LQ, et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transpl. 2012;47(9):1186–1190.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Young NS. How i treat acquired aplastic anemia. Blood. 2012;120(6):1185–1196.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cao Y, Li X, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild gvhd. Stem Cell Res. 2014;12(1):132–138.
   PubMed Web of Science ®Google Scholar
• Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transpl. 2006;12(12):1277–1284.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the ebmt-saa working party. Haematol. 2010;95(6):976–982.
   PubMed Web of Science ®Google Scholar
• Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donor bmt and unrelated donor bmt in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transpl. 2010;45(10):1508–1513.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu L, Mo W, et al. Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: A retrospective single-center study. Biol Blood Marrow Transpl. 2019;25(8):1567–1575.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Giammarco S. Haploidentical donor transplants for severe aplastic anemia. Semin Hematol. 2019;56(3):190–193.
   PubMed Web of Science ®Google Scholar
• Im HJ, Koh KN, Choi ES, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transpl. 2013;19(5):754–759.
   PubMed Web of Science ®Google Scholar
• Gao L, Li Y, Zhang Y, et al. Long-term outcome of hla-haploidentical hematopoietic sct without in vitro t-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transpl. 2014;49(4):519–524.
   PubMed Web of Science ®Google Scholar
• Clay J, Kulasekararaj AG, Potter V, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2014;20(11):1711–1716.
   PubMed Web of Science ®Google Scholar
• Esteves I, Bonfim C, Pasquini R, et al. Haploidentical bmt and post-transplant cy for severe aplastic anemia: A multicenter retrospective study. Bone Marrow Transpl. 2015;50(5):685–689.
   PubMed Web of Science ®Google Scholar
• Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
   PubMed Web of Science ®Google Scholar
• Prata PH, Eikema DJ, Afansyev B, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: A report from the ebmt severe aplastic anemia working party. Bone Marrow Transpl. 2020;55(6):1050–1058.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Alternative donor transplants for severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018(1):467–473.
   PubMedGoogle Scholar
• Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese society of hematology. J Hematol Oncol. 2018;11(1):33.
   PubMedGoogle Scholar
• Bejanyan N, Kim S, Hebert KM, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123–3131.
   PubMed Web of Science ®Google Scholar
• Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2013;2013(1):76–81.
   PubMedGoogle Scholar
• Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transpl. 2005;35(10):1011–1018.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhao X, Tian Y, et al. Outcomes of peripheral blood stem cell transplantation patients from hla-mismatched unrelated donor with antithymocyte globulin (atg)-thymoglobulin versus atg-fresenius: A single-center study. Med Oncol. 2015;32(2):465.
   PubMed Web of Science ®Google Scholar
• Polverelli N, Malagola M, Turra A, et al. Comparative study on atg-thymoglobulin versus atg-fresenius for the graft-versus-host disease (gvhd) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: A single-centre experience over the contemporary years. Leuk Lymph. 2018;59(11):2700–2705.
   PubMed Web of Science ®Google Scholar
• Penack O, Fischer L, Gentilini C, et al. The type of atg matters – natural killer cells are influenced differentially by thymoglobulin, lymphoglobulin and atg-fresenius. Transpl Immunol. 2007;18(2):85–87.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (saa): A prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826–831.
   PubMed Web of Science ®Google Scholar
• Bing H, Siyi Y, Wei Z, et al. The use of anti-human t lymphocyte porcine immunoglobulin and cyclosporine a to treat patients with acquired severe aplastic anemia. Acta Haematol. 2010;124(4):245–250.
   PubMed Web of Science ®Google Scholar
• Liu L, Ding L, Hao L, et al. Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia. Ann Hematol. 2015;94(5):729–737.
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of sf-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care. 1995;33(4 Suppl):264–279.
   Web of Science ®Google Scholar
• Li L, Wang HM, Shen Y. Chinese sf-36 health survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health. 2003;57(4):259–263.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Yagasaki H, Kojima S, Yabe H, et al. Acceptable hla-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood. 2011;118(11):3186–3190.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: A study by eurocord and the aplastic anemia working party of the european group for blood and marrow transplantation. Biol Blood Marrow Transpl. 2011;17(1):78–85.
   PubMed Web of Science ®Google Scholar
• Xu LP, Liu KY, Liu DH, et al. A novel protocol for haploidentical hematopoietic sct without in vitro t-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transpl. 2012;47(12):1507–1512.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: A systematic review. Leukemia. 2012;26(4):582–588.
   PubMed Web of Science ®Google Scholar
• Paiano S, Roosnek E, Tirefort Y, et al. Comparing two types of rabbit atg prior to reduced intensity conditioning allogeneic hematopoietic sct for hematologic malignancies. Bone Marrow Res. 2015;2015:980924.
   PubMedGoogle Scholar
• Kekre N, Zhang Y, Zhang MJ, et al. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematol. 2017;102(7):1291–1298.
   PubMed Web of Science ®Google Scholar
• Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the bone marrow transplant survivor study. Blood. 2004;104(6):1898–1906.
   PubMed Web of Science ®Google Scholar
• Worel N, Biener D, Kalhs P, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transpl. 2002;30(9):619–626.
   PubMed Web of Science ®Google Scholar
• Mo XD, Xu LP, Liu DH, et al. Patients receiving hla-haploidentical/partially matched related allo-hsct can achieve desirable health-related qol that is comparable to that of patients receiving hla-identical sibling allo-hsct. Bone Marrow Transpl. 2012;47(9):1201–1205.
   PubMed Web of Science ®Google Scholar
• Wong FL, Francisco L, Togawa K, et al. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood. 2010;115(12):2508–2519.
   PubMed Web of Science ®Google Scholar
• Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the bone marrow transplant survivor study. Blood. 2006;108(8):2867–2873.
   PubMed Web of Science ®Google Scholar